TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Amplia Therapeutics ( (AU:ATX) ) is now available.
Amplia Therapeutics Limited has announced a change in the director’s interest notice for Jane Bell, reflecting recent changes in her holdings of shares and options. This update is part of the company’s ongoing compliance with ASX listing rules and demonstrates transparency in its corporate governance practices.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company has a particular emphasis on fibrotic cancers such as pancreatic cancer and chronic diseases like idiopathic pulmonary fibrosis (IPF).
YTD Price Performance: 74.16%
Average Trading Volume: 7,216,964
Technical Sentiment Signal: Hold
Current Market Cap: A$79.53M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.